02140nam a2200469 i 4500001001300000003000600013005001700019007001400036008004100050040002800091042000800119043001200127050002100139074001600160086002000176110008200196245017300278264007100451300002300522336000800545337001600553338001900569490007700588500002400665500002100689500003700710500002500747504004100772533010600813610004100919610007000960650001401030650001401044650005101058650005101109650005601160650006701216655003401283776014701317776014801464810005801612on1062363418OCoLC20181217092328.0he bmb024bbca181109s2018    dcu     bb   f000 0 eng c  aGPObengerdacGPOdMvI  apcc  an-us--- 4aKF32b.E55 2018v  a1008-D (MF)0 aY 1.1/8:115-7261 aUnited States.bCongress.bHouse.bCommittee on Energy and Commerce,eauthor.10aMedicaid Pharmaceutical Home Act of 2018 :breport together with additional views (to accompany H.R. 5808) (including cost estimate of the Congressional Budget Office). 1a[Washington, D.C.] :b[U.S. Government Publishing Office],c[2018]  a36 pages ;c24 cm.  btxt  bh2rdamedia  bhe2rdacarrier1 aReport / 115th Congress, 2d session, House of Representatives ;v115-726  aTitle from caption.  a"June 12, 2018."  aShipping list no.: 2018-00192-M.  aCRDP Program record.  aIncludes bibliographical references.  aMicrofiche.b[Washington, D.C.] :cU.S. Government Printing Office,d[2018]e1 microfiche : negative.10aUnited States.tSocial Security Act.10aUnited States.bFood and Drug AdministrationxRules and practice. 0aMedicaid. 0aMedicare. 0aDrugsxPrescribingzUnited StatesxManagement. 0aOpioid abusexTreatmentzUnited StatesxCosts. 0aDrug developmentxGovernment policyzUnited States. 0aDrugsxGeneric substitutionxGovernment policyzUnited States. 7aLegislative materials.2lcgft08iPrint version:aUnited States. Congress. House. Committee on Energy and Commerce.tMedicaid Pharmaceutical Home Act of 2018w(OCoLC)104208603208iOnline version:aUnited States. Congress. House. Committee on Energy and Commerce.tMedicaid Pharmaceutical Home Act of 2018w(OCoLC)10420748921 aUnited States.bCongress.bHouse.tReport ;v115-726.